恒瑞医药：收到6个药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine has received clinical trial approval notices for six drug candidates from the National Medical Products Administration, indicating a significant advancement in its research and development efforts [1] Summary by Category Clinical Trials - The company and its subsidiaries have been approved to conduct clinical trials for the following drugs: SHR2554 tablets, SHR-A1811 injection, SHR-A2102 injection, Adebeli monoclonal antibody injection, SHR-A1904 injection, and SHR-1701 injection [1] Research and Development Investment - The cumulative R&D investments for these projects are as follows: - SHR2554 tablets: approximately 180 million yuan - SHR-A1811 injection: approximately 1.17 billion yuan - SHR-A2102 injection: approximately 205 million yuan - Adebeli monoclonal antibody injection: approximately 887 million yuan - SHR-A1904 injection: approximately 143 million yuan - SHR-1701 injection: approximately 674 million yuan [1]